Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular EdemaAmerican journal of ophthalmology, 2022-06, Vol.238, p.157-172 [Peer Reviewed Journal]2022 ;Copyright © 2022. Published by Elsevier Inc. ;Copyright Elsevier Limited Jun 2022 ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2022.01.004 ;PMID: 35038415Full text available |
|
2 |
Material Type: Article
|
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular EdemaThe New England journal of medicine, 2015-03, Vol.372 (13), p.1193-1203 [Peer Reviewed Journal]Copyright © 2015 Massachusetts Medical Society. All rights reserved. ;Copyright © 2015 Massachusetts Medical Society. 2015 ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1414264 ;PMID: 25692915Full text available |
|
3 |
Material Type: Article
|
Pharmacology of Corticosteroids for Diabetic Macular EdemaInvestigative ophthalmology & visual science, 2018-01, Vol.59 (1), p.1-12 [Peer Reviewed Journal]Copyright 2018 The Authors 2018 ;ISSN: 1552-5783 ;ISSN: 0146-0404 ;EISSN: 1552-5783 ;DOI: 10.1167/iovs.17-22259 ;PMID: 29297055Full text available |
|
4 |
Material Type: Article
|
Effect of Intravitreous Anti–Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical TrialArchives of ophthalmology (1960), 2021-07, Vol.139 (7), p.701 [Peer Reviewed Journal]Copyright American Medical Association Jul 2021 ;ISSN: 2168-6165 ;EISSN: 1538-3601 ;DOI: 10.1001/jamaophthalmol.2021.0606Full text available |
|
5 |
Material Type: Article
|
Early and Long-term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I DataAmerican journal of ophthalmology, 2016-12, Vol.172, p.72-79 [Peer Reviewed Journal]2016 The Authors ;Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Dec 01, 2016 ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2016.09.012 ;PMID: 27644589 ;CODEN: AJOPAAFull text available |
|
6 |
Material Type: Article
|
Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working GroupEye (London), 2020-06, Vol.34 (Suppl 1), p.1-51 [Peer Reviewed Journal]The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2020. ;The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2020 ;ISSN: 0950-222X ;EISSN: 1476-5454 ;DOI: 10.1038/s41433-020-0961-6 ;PMID: 32504038Full text available |
|
7 |
Material Type: Article
|
Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyesBritish journal of ophthalmology, 2021-02, Vol.105 (2), p.216-221 [Peer Reviewed Journal]Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2021 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2021 ;ISSN: 0007-1161 ;EISSN: 1468-2079 ;DOI: 10.1136/bjophthalmol-2020-315933 ;PMID: 32265201Full text available |
|
8 |
Material Type: Article
|
Association of Predominantly Peripheral Lesions on Ultra-Widefield Imaging and the Risk of Diabetic Retinopathy Worsening Over TimeArchives of ophthalmology (1960), 2022-10, Vol.140 (10), p.946 [Peer Reviewed Journal]Copyright American Medical Association Oct 2022 ;ISSN: 2168-6165 ;EISSN: 1538-3601 ;DOI: 10.1001/jamaophthalmol.2022.3131Full text available |
|
9 |
Material Type: Article
|
Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN studyBritish journal of ophthalmology, 2016-06, Vol.100 (6), p.787-795 [Peer Reviewed Journal]Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing ;Copyright: 2016 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ 2016 ;ISSN: 0007-1161 ;EISSN: 1468-2079 ;DOI: 10.1136/bjophthalmol-2015-307249 ;PMID: 26453639 ;CODEN: BJOPALFull text available |
|
10 |
Material Type: Article
|
Association of Ultra-Widefield Fluorescein Angiography–Identified Retinal Nonperfusion and the Risk of Diabetic Retinopathy Worsening Over TimeArchives of ophthalmology (1960), 2022-10, Vol.140 (10), p.936 [Peer Reviewed Journal]Copyright American Medical Association Oct 2022 ;ISSN: 2168-6165 ;EISSN: 1538-3601 ;DOI: 10.1001/jamaophthalmol.2022.3130Full text available |
|
11 |
Material Type: Article
|
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study): A 12-month, randomized, controlled, double-masked, multicenter phase II studyDiabetes care, 2010-11, Vol.33 (11), p.2399-2405 [Peer Reviewed Journal]2015 INIST-CNRS ;COPYRIGHT 2010 American Diabetes Association ;Copyright American Diabetes Association Nov 2010 ;2010 by the American Diabetes Association. ;ISSN: 0149-5992 ;EISSN: 1935-5548 ;DOI: 10.2337/dc10-0493 ;PMID: 20980427 ;CODEN: DICAD2Full text available |
|
12 |
Material Type: Article
|
NSAIDs and Corticosteroids for the Postoperative Management of Age-Related Cataract Surgery: A Systematic Review and Meta-analysisAmerican journal of ophthalmology, 2024-04, Vol.260, p.1-13 [Peer Reviewed Journal]2023 Elsevier Inc. ;Copyright © 2023 Elsevier Inc. All rights reserved. ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2023.09.027 ;PMID: 37797866Full text available |
|
13 |
Material Type: Article
|
Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 PatientsAmerican journal of ophthalmology, 2019-04, Vol.200, p.85-94 [Peer Reviewed Journal]2019 Elsevier Inc. ;Copyright © 2019 Elsevier Inc. All rights reserved. ;2019. Elsevier Inc. ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2018.12.019 ;PMID: 30660771Full text available |
|
14 |
Material Type: Article
|
Anti-vascular endothelial growth factor for diabetic macular oedemaCochrane database of systematic reviews, 2014-10 (10), p.CD007419-CD007419 [Peer Reviewed Journal]EISSN: 1469-493X ;DOI: 10.1002/14651858.CD007419.pub4 ;PMID: 25342124Full text available |
|
15 |
Material Type: Article
|
Long-Term Visual Outcomes and Morphologic Biomarkers of Vision Loss in Eyes With Diabetic Macular Edema Treated With Anti-VEGF TherapyAmerican journal of ophthalmology, 2022-03, Vol.235, p.80-89 [Peer Reviewed Journal]2021 Elsevier Inc. ;Copyright © 2021 Elsevier Inc. All rights reserved. ;2021. Elsevier Inc. ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2021.09.002 ;PMID: 34509431Full text available |
|
16 |
Material Type: Article
|
Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNVBritish journal of ophthalmology, 2017-03, Vol.101 (3), p.353-359 [Peer Reviewed Journal]Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/. ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/2017This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:http://creativecommons.org/licenses/by-nc/4.0 ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ 2017 ;ISSN: 0007-1161 ;EISSN: 1468-2079 ;DOI: 10.1136/bjophthalmol-2016-308668 ;PMID: 27215744Full text available |
|
17 |
Material Type: Article
|
Long-term efficacy and safety profile of multiple injections of intravitreal dexamethasone implant to manage diabetic macular edema: A systematic review of real-world studiesJournal of pharmacological sciences, 2018-12, Vol.138 (4), p.219-232 [Peer Reviewed Journal]2018 The Authors ;Copyright © 2018 The Authors. Production and hosting by Elsevier B.V. All rights reserved. ;ISSN: 1347-8613 ;EISSN: 1347-8648 ;DOI: 10.1016/j.jphs.2018.11.001 ;PMID: 30503676Full text available |
|
18 |
Material Type: Article
|
Association Between Soluble CD14 in the Aqueous Humor and Hyperreflective Foci on Optical Coherence Tomography in Patients With Diabetic Macular EdemaInvestigative ophthalmology & visual science, 2018-02, Vol.59 (2), p.715-721 [Peer Reviewed Journal]ISSN: 1552-5783 ;EISSN: 1552-5783 ;DOI: 10.1167/iovs.17-23042 ;PMID: 29392317Full text available |
|
19 |
Material Type: Article
|
Early Response to Anti–Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol TAmerican journal of ophthalmology, 2018-11, Vol.195, p.93-100 [Peer Reviewed Journal]2018 Elsevier Inc. ;Copyright © 2018 Elsevier Inc. All rights reserved. ;COPYRIGHT 2018 Elsevier B.V. ;Copyright Elsevier Limited Nov 2018 ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2018.07.030 ;PMID: 30077569Full text available |
|
20 |
Material Type: Article
|
KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular EdemaAmerican journal of ophthalmology, 2024-04, Vol.260, p.70-83 [Peer Reviewed Journal]2023 The Author(s) ;Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved. ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2023.07.012 ;PMID: 37460036Full text available |